Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA

Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…

AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug

3 months / endpoints / ENDPOINTS

Immedica wins accelerated approval for once-rejected rare disease drug

3 months / endpoints / Zachary Brennan

FDA proposes new system for approving customized drugs and therapies for rare diseases

3 months / medicalxpress

FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher

3 months / endpoints / Max Gelman

Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA

3 months / medcitynews / Frank Vinluan

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA

Related Stories